Abstract
Anaplastic thyroid carcinoma is arguably the most lethal human malignancy. It often co-occurs with differentiated thyroid cancers, yet the molecular origins of its aggressivity are unknown. We sequenced tumor DNA from 329 regions of thyroid cancer, including 213 from patients with primary anaplastic thyroid carcinomas and multi-region whole-genome sequencing. Anaplastic thyroid carcinomas have a higher burden of mutations than other thyroid cancers, with distinct mutational signatures and molecular subtypes. Specific cancer driver genes are mutated in anaplastic and differentiated thyroid carcinomas, even those arising in a single patient. We unambiguously demonstrate that anaplastic thyroid carcinomas share a genomic origin with co-occurring differentiated carcinomas, and emerge from a common malignant field through acquisition of characteristic clonal driver mutations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Canadian Institutes of Health Research grant MOP 377832 to ACN and PCB, MOP 145586 to PCB and by the Government of Canada through Genome Canada and the Ontario Genomics Institute (OGI-125). NA, BN and DB were supported by a Julius Edlow Pilot Research grant. PCB was supported by CIHR and Terry Fox Research Institute New Investigator Awards and by the Ontario Institute for Cancer Research to PCB through funding provided by the Government of Ontario. This work was further supported by National Institutes of Health and Medical Research Grants R01 CA136665 (to JAC and RCS), Florida Department of Health Bankhead-Coley Cancer Research Program Grant FL09B202 (JAC and RCS), Mayo Comprehensive Cancer Center Grant P30CA01508343 (RCS), UCLA Comprehensive Cancer Center Grant P30CA016042 (PCB), by the NIH/NCI through support from the ITCR (1U24CA248265-01 (PCB), as well as support from Alfred D. and Audrey M. Petersen (RCS), the Francis and Miranda Childress Foundation Fund for Cancer Research (JAC), the John A. and Bette B. Klacsmann Fund for Cancer Research at the Mayo Clinic in Florida (JAC), the Bruno V. and Bruce E. Zanoni Endowed Research Fund (JAC), the Betty G. Castigliano Fund in Cancer Research Honoring S. Gordon Castigliano, MD, Cancer Research at the Mayo Clinic Florida (JAC), and the Dewitt C. (Dash) Goff Fund for thyroid cancer research (JAC). This work was also supported through generous donations by: 1) the Marty Schaffel Thyroid Cancer Research Fund (MD Anderson Cancer Center, Houston, Texas), 2) London Health Sciences Foundation (Robert and Sheila Wilkes, Betty and Harry Ostrander, Mervyn and Joyce Dietz) and 3) the Woodstock Foundation (Laila, Arnold, Mario, Andrea, Tony and Tomassina Spina, Susan and Bill George, Piero and Maria Manzini, Henry and Rina Deroo, Harry and Shani Loewith, Franco and Carol Castellucci, Tony and Bill Van Haeren, Billy and Jennifer Stevanovich, Tom and Pat Baird, Christine and Jeff Nichols, Cliff and Linda Zaluski, Thomas Vandertuin, Laurie and Paul Green, Kelli and Mike Koopman). ACN was supported by the Wolfe Surgical Research Professorship in the Biology of Head and Neck Cancers Fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Research Ethics Boards at Western University (REB 7182) and informed consent was obtained from each patient.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Abstract and title updated
Data Availability
All data will be available via request to ACN (anthony.nichols{at}lhsc.on.ca)
